Zicom Group

Technology, Engineering,

Manufacturing

Corporate Structure

Zicom Group

(Listed on ASX)

Precision Engineering & Technologies Cluster

Zicom MedTacc

(Investments & Commercialization)

Iptec

(Technology Development)

Sysmac

(Manufacturing)

Construction Equipment Cluster

Marine, Oil & Gas Cluster

Key Information

• Founded in 1978. Currently listed on ASX.

• Employees > 700. Employee ownership in Zicom > 55%

• Direct presence in Singapore (HQ), Australia, Indonesia, Thailand, China, USA

• Business awards: Enterprise 50, Singapore 1000, Ernst & Young Entrepreneur 2008

1. Zicom Pte Ltd

2. Zicom Equipment

1. Foundation Associates

2. FA Geotech

3. Cesco Australia

4. Cesco Equipment

5. Hangzhou Cesco

6. Zicom Cesco Engineering

7. Zicom Thai Hydraulics

1. Zicom MedTacc

2. Iptec

3. Sys-Mac

4. MTA-Sysmac

5. PT Sysmac

6. Biobot Surgical

7. Curiox Biosystems

8. Orion Systems

9. Histoindex

Group Companies by Cluster

Our Key Clusters

Principal Products

• Anchor handling towing systems,

Mooring systems, Pipe laying systems.

• Natural gas processing plants,

regulating and metering skids.

• Average value of projects range from

US$1m to US$30m

Customers

• Ministry of Transport, China

• Petroblanga, ONGC, Chevron

Principal Products

• Mobile mixers: used for

transportation and mixing of concrete

carrying loads of 2m3 to 9m3

• Customized mixers: tanning of

leather, mixing of explosives.

• Foundation equipment: piling and

strengthening foundation of buildings

and infrastructures (onshore and

offshore)

Customers

• Readymix companies such as

Hanson, Boral

• Civil construction contractors

• Oil majors such as Haliburton

Principal Activities - Automation Engineering, Contract Product

Manufacturing, Design & Development

Life Sciences & MedTechConsumer Electronics & Semi-Con

Construction Equipment Marine, Oil & Gas Precision Technology & Engineering

Brief Overview of Zicom MedTacc Group

Vision

To be a leading Asian Medtech Commercialization Group

• $30M accelerator fund with co-investor SPRING (statutory board under Ministry of Trade and Industry)

• Accelerator Group has more than 30 experienced professionals and subject matter experts.

• Provide a holistic commercialization platform for medical technologies. Key expertise include:

• IP Translation

• Regulatory Affairs and Quality Assurance

• Commercial and Clinical Partnerships

• Marketing and Sales Creation

Senior Leadership

Mr. Sim Giok Lak,

Executive Chairman,

Zicom Group

• Founder & Chairman, Zicom

• Director of SPRING

• Member, Biomed Panel, ETPL

• Member, SAB, DxD Hub

• Member, SNEC Incubation Board

• E&Y Entrepreneur 2008 (Industrial)

Engineering & Manufacturing

Mr Sim Kok Yew,

CEO, Sys-Mac

• CEO, Sys-Mac

Group

• Executive Director,

Zicom Group

• Director of Biobot,

Curiox

Mr Gary Lee

CEO, IPTEC

• Previously held

management

positions in

Jabil,

Flextronics,

Sakura Tech, &

Allied

Technologies

Investments & Commercialization

Mr Sim Kok Hwee,

CEO

• Executive Director,

Zicom Group

• Member, Evaluation

Panel, DxD Hub

Mr Peter Cheng

CTO

• Previously held R&D

mgmt positions in Hyflux,

Vestas, Philips

• Member, TECS Panel,

SPRING

Dr Lim Chee Tiong

VP, Commercial

• Previously Asst

Director of MTO,

SingHealth

• R&D Engineer with

J&J

Ms Liew Lai Chee

VP, RA &QA

• More than 20 years

experience in regulatory and

QA

• Previously held management

positions with GE Healthcare

& Covidien

Dr Emril Ali

VP, ANZ

• Previously Senior

Manager, ETPL,

A*Star

• R&D Engineer, IBN,

A*Star

Ms Jenny Lim

CFO

• Group Financial

Controller Zicom Group

• Previously Senior

Manager with EY Audit

Assurance and Taxation

Our Clinical Advisers

A/Professor Choolani leads the High-Risk pregnancy Unit of

Maternal-Fetal Medicine Division at the National University

Hospital (NUH), where he and his team were instrumental in

the development of the breakthrough FlashFISH™ technology.

FlashFISH™ is a rapid diagnostic test performed during

amniocentesis that can detect Down syndrome in unborn

babies within three hours.

He is the principle founder of INEX and non-executive director

of the company, and is one of the key drivers in the successful

development of INEX from a small biotech start-up to a leading

women’s health diagnostic company.

A/Professor Choolani received the Benjamin Henry Sheares’

Memorial Lecture Award in 2010 for his outstanding work in

Obstetrics and Gynaecology. He has also been awarded the

National Medical Research Council (NMRC) Clinician Scientist

award for his outstanding contribution to research.

He has published over 100 articles and abstracts in notable

journals and currently chairs the National University of

Singapore’s Leadership in Academic Medicine Clinician

Scientist Unit and the National Healthcare Group’s Clinician

Leadership Research programme

“We Engineer & Manufacture”

Dr Bhuwnesh Agrawal is an industry veteran with a career

in academic and corporate positions spanning over 35

years. He is currently Vice President, Asia Pac and Africa

of Eppendorf AG.

Dr Agrawal spent 15 years at the Free University of Berlin

in research, teaching and patient management at the start

of his career. Subsequently, he worked in the

pharmaceuticals and diagnostics divisions of Boehringer

Mannheim/Roche in a variety of roles from clinical

research, strategy and business development, to

marketing and sales, for more than 20 years.

He has also held various local, regional, global and

corporate responsibilities in Germany, Switzerland and

India, from where he headed the South Asia business for

Roche Diagnostics from 2007-2012 before joining Vela

Diagnostics.

Dr Agrawal is a medical doctor by training with

specializations in Internal Medicine, Clinical

Pharmacology, and Pharmacology and Toxicology from

Germany. He also received his MBA from the Open

University, UK and his PhD from the Free University of

Berlin.

Dr Henry Ho is a Senior Consultant with the department of

urology in Singapore General Hospital. He is also the

Director of the MedTech Office of SingHealth, responsible

for developing innovative medtech solutions within the

SingHealth Group.

He is one of the 3 pioneering urologists involved in the

development of Biobot’s robotic prostate intervention device

that is a first in the world that puts Singapore in the world

map of Urology.

His main research interest is medical engineering. His other

research interests are medical imaging, ablative energy

technology and non-invasive bladder evaluation.

After completing his undergraduate medical degree in

National University of Singapore, he underwent surgical

training to be a general surgeon and sub specialized to an

urologist. Henry completed a clinical Fellowship in robotic

uro-oncology with Prof G Bartsch, Innsbruck, Austria,

followed by Fellowship in Endourology and laser

prostatectomy with Prof A Gross, Hamburg Germany.

Henry's specialty interests lies in minimally-invasive

urological surgery, benign prostate enlargement and uro-

oncology

Assoc. Prof.

Henry Ho

Senior Consultant

Urologist, SGH

Director of MTO,

SingHealth

Assoc. Prof.

Mahesh Choolani

Senior Consultant

ObGyn, NUH

Director of Research

ObGyn, NUHDr. Bhuwnesh Agrawal

VP, Asia Pac & Africa

Eppendorf AG

Marketing to Early Adopters

• Engagement with early adopters

• Identify appropriate market access consultants &

distributors

Hands On Mentorship

• Singapore based Silver Mentors possessing strategic, industrial, & commercialization experiences

• Focused on grooming startup C-level executives

Network

• Key stakeholder in Singapore’s BioMed ecosystem

• Portfolio companies revenue generating, contributing to

growing market access network

Infrastructure – Commercialization

Mr. GL Sim

• Founder & Chairman, Zicom

• Director of SPRING

• Member, Biomed Panel,

ETPL

• Member, SAB, DxD Hub

• Member, SNEC Incubation

Board

• E&Y Entrepreneur 2008

(Industrial)

Mr. Jim Finley

• Angel investor

• Retired as EVP of

Rolls Royce,

Energy Division

Mr. CL Yap

• Angel investor

• Formerly held

management positions

in ETPL, Becton

Dickinson, ST

Engineering

Mr. R Govindan

• Founder & Chairman,

Mercatus Capital

• Serial entrepreneur &

investor

• Former President of

Fisher Scientific, APAC

Mr KW Ong

• Founder & Director,

Mercatus Capital

• Serial entrepreneur

& investor

• Former CEO of CH

Offshore

Our BioMed Portfolio

Minimally invasive robotic platform for targeted prostate biopsy

- MRI-Targeted Biopsy enabled

- FDA, CE, TGA, HSA approved.

- More than 800 patients

- ISO 13485

- Centers of Excellence in Germany, New York, Australia, UK

- Developing treatment applications

Bioinstrumentation for drug discovery

- Validated by top 10 global pharma companies

- Tech leader for suspension cells & luminex based assays

- San Francisco subsidiary

3-D, quantitative, laser-based imaging for tissue diagnostic

- CE approved. FDA, CFDA in process.

- ISO 13485

- Hangzhou subsidiary

- > 3,000 patients tissue samples analyzed for liver diseases

- Tissue Imaging Service Centers in USA, China, Singapore

Biobot SurgicalBackground IP:

SGH, NTU

Curiox BiosystemsBackground IP: A*Star

HistoindexBackground IP: A*Star

“We Engineer & Manufacture”

Our BioMed Portfolio

Prenatal & Women’s Health Diagnostics

- ISO 13485

- Joint lab BGI to offer non-invasive prenatal testing

- Ovacis intra-operative diagnostic kit used to determine

malignancy of ovarian cancer. Results in < 5mins

Medical Imaging Management

- Software solution to transmit and manage image files in

DICOM format for radiology, pathology, & ophthalmology

- Software integration partner for Topcon Japan.

- Developing national screening platform for retinopathy for SNEC, Singhealth & NHG. Contract awarded by MOHH.

InexBackground IPs: NUS

Pellucid

“We Engineer & Manufacture”

Thank You